Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in: Diabetes Therapy 1/2012

Open Access 01-12-2012 | Review

Management of Diabetic Foot Ulcers

Authors: Kleopatra Alexiadou, John Doupis

Published in: Diabetes Therapy | Issue 1/2012

Login to get access

Abstract

Diabetic foot is a serious complication of diabetes which aggravates the patient’s condition whilst also having significant socioeconomic impact. The aim of the present review is to summarize the causes and pathogenetic mechanisms leading to diabetic foot, and to focus on the management of this important health issue. Increasing physicians’ awareness and hence their ability to identify the “foot at risk,” along with proper foot care, may prevent diabetic foot ulceration and thus reduce the risk of amputation.
Literature
1.
Abbott CA, Carrington AL, Ashe H, North-West Diabetes Foot Care Study, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377–84.PubMedCrossRef
2.
Centers for Disease Control and Prevention. Lower extremity disease among persons aged ≥40 years with and without diabetes—United States, 1999–2002. MMWR Morb Mortal Wkly Rep. 2005;54:1158–60.
3.
Lauterbach S, Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care. 2010;19:333–7.PubMed
4.
Katsilambros N, Dounis E, Makrilakis K, Tentolouris N, Tsapogas P. Atlas of the diabetic foot. 2nd ed. Oxford: Wiley-Blackwell; 2010.CrossRef
5.
Moxey PW, Gogalniceanu P, Hinchliffe RJ, et al. Lower extremity amputations—a review of global variability in incidence. Diabet Med. 2011;28:1144–53.PubMedCrossRef
6.
Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med. 1998;158:157–62.PubMedCrossRef
7.
Malgrange D, Richard JL, Leymarie F, French Working Group On The Diabetic Foot. Screening diabetic patients at risk for foot ulceration. A multi-centre hospital-based study in France. Diabetes Metab. 2003;29:261–8.PubMedCrossRef
8.
Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia. 2008;51:1826–34.PubMedCrossRef
9.
Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med. 1994;11:480–4.PubMedCrossRef
10.
Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377–84.PubMedCrossRef
11.
Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. Am J Surg. 2004;187:1S–10S.PubMedCrossRef
12.
Bowering CK. Diabetic foot ulcers. Pathophysiology, assessment, and therapy. Can Fam Physician. 2001;47:1007–16.PubMed
13.
Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19(Suppl. A):S1–250.
14.
Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18–25.PubMedCrossRef
15.
16.
Benotmane A, Mohammedi F, Ayad F, Kadi K, Azzouz A. Diabetic foot lesions: etiologic and prognostic factors. Diabetes Metab. 2000;26:113–7.PubMed
17.
Hoffman AF. Evaluation of arterial blood flow in the lower extremity. Clin Podiatr Med Surg. 1992;9:19–56.PubMed
18.
Puttemans T, Nemery C. Diabetes: the use of color Doppler sonography for the assessment of vascular complications. Eur J Ultrasound. 1998;7:15–22.PubMedCrossRef
19.
Williams DT, Harding KG, Price P. An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. Diabetes Care. 2005;28:2206–10.PubMedCrossRef
20.
Kravitz SR, McGuire J, Shanahan SD. Physical assessment of the diabetic foot. Adv Skin Wound Care. 2003;16:68–75.PubMedCrossRef
21.
Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Maltezos E. Association between foot temperature and sudomotor dysfunction in type 2 diabetes. J Diabetes Sci Technol. 2010;4:803–7.PubMed
22.
Armstrong DG, Holtz-Neiderer K, Wendel C, Mohler MJ, Kimbriel HR, Lavery LA. Skin temperature monitoring reduces the risk for diabetic foot ulceration in high-risk patients. Am J Med. 2007;120:1042–6.PubMedCrossRef
23.
Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002;19:962–5.PubMedCrossRef
24.
Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976–82.PubMedCrossRef
25.
Boulton AJ, Armstrong DG, Albert SF, American Diabetes Association; American Association of Clinical Endocrinologists, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31:1679–85.PubMedCrossRef
26.
Perkins BA, Orszag A, Ngo M, Ng E, New P, Bril V. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33:1549–54.PubMedCrossRef
27.
Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20(Suppl. 1):S90–5.PubMedCrossRef
28.
Doupis J, Veves A. Classification, diagnosis, and treatment of diabetic foot ulcers. Wounds. 2008;20:117–26.
29.
Hinchliffe RJ, Valk GD, Apelqvist J, et al. Specific guidelines on wound and wound-bed management. Diabetes Metab Res Rev. 2008;24(Suppl. 1):S188–9.PubMedCrossRef
30.
Lebrun E, Tomic-Canic M, Kirsner RS. The role of surgical debridement in healing of diabetic foot ulcers. Wound Repair Regen. 2010;18:433–8.PubMedCrossRef
31.
Smith RG. Enzymatic debriding agents: an evaluation of the medical literature. Ostomy Wound Manage. 2008;54:16–34.PubMed
32.
Margolin L, Gialanella P. Assessment of the antimicrobial properties of maggots. Int Wound J. 2010;7:202–4.PubMedCrossRef
33.
Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG. Wound dressings in diabetic foot disease. Clin Infect Dis. 2004;39(Suppl. 2):S100–3.PubMedCrossRef
34.
Saap LJ, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen. 2002;10:354–9.PubMedCrossRef
35.
Game FL, Hinchliffe RJ, Apelqvist J, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28(Suppl. 1):119–41.PubMedCrossRef
36.
Veves A, Murray HJ, Young MJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetologia. 1992;35:660–3.PubMedCrossRef
37.
Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care. 2000;23:606–11.PubMedCrossRef
38.
Frykberg RG, Lavery LA, Pham H, Harvey C, Harkless L, Veves A. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care. 1998;21:1714–9.PubMedCrossRef
39.
Pound N, Chipchase S, Treece K, Game F, Jeffcoate W. Ulcer-free survival following management of foot ulcers in diabetes. Diabet Med. 2005;22:1306–9.PubMedCrossRef
40.
Burns J, Begg L. Optimizing the offloading properties of the total contact cast for plantar foot ulceration. Diabet Med. 2011;28:179–85.PubMedCrossRef
41.
Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. J Vasc Surg. 2010;52(Suppl.):37S–43S.PubMedCrossRef
42.
Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care. 2005;28:551–4.PubMedCrossRef
43.
Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001;24:1019–22.PubMedCrossRef
44.
Clark RAF. Wound repair: overview and general considerations. In: Clark RAF, editor. The molecular and cellular basis of wound repair. New York: Plenum Press; 1996. p. 3–50.
45.
Harding KG, Jones V, Price P. Topical treatment: which dressing to choose. Diabetes Metab Res Rev. 2000;16(Suppl. 1):S47–50.PubMedCrossRef
46.
Olson ME, Wright JB, Lam K, Burrell RE. Healing of porcine donor sites covered with silver-coated dressings. Eur J Surg. 2000;166:486–9.PubMedCrossRef
47.
Tredget EE, Shankowsky HA, Groeneveld A, Burrell R. A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil. 1998;19:531–7.PubMedCrossRef
48.
Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010;33:455–61.PubMedCrossRef
49.
Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21:71–8 (discussion 79–81).
50.
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21:822–7.PubMedCrossRef
51.
52.
Yang HS, Shin J, Bhang SH, et al. Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma. Exp Mol Med. 2011;43:622–9.PubMedCrossRef
53.
Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24:483–8.PubMedCrossRef
54.
Driver VR, Hanft J, Fylling CP, Beriou JM, Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52:68–70, 72, 74 passim.
55.
Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev. 2009;(8):CD006810.
56.
Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28:2155–60.PubMedCrossRef
57.
de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother. 2001;45:1094–8.PubMedCrossRef
58.
Yönem A, Cakir B, Güler S, Azal OO, Corakçi A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab. 2001;3:332–7.PubMedCrossRef
59.
Uchi H, Igarashi A, Urabe K, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009;19:461–8.PubMed
60.
Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care. 1995;18:64–9.PubMedCrossRef
61.
Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J. 2009;6:159–66.
62.
Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26:1856–61.PubMedCrossRef
63.
Edmonds M, Bates M, Doxford M, Gough A, Foster A. New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev. 2000;16(Suppl. 1):S51–4.PubMedCrossRef
64.
Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 2006;12:2407–24.PubMedCrossRef
65.
Uccioli L, Giurato L, Ruotolo V, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds. 2011;10:80–5.PubMedCrossRef
66.
Moustafa M, Simpson C, Glover M, et al. A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet Med. 2004;21:786–9.PubMedCrossRef
67.
Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18:258–66.PubMedCrossRef
68.
Martin BR, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2005;2:161–5.PubMedCrossRef
69.
Mansbridge J. Skin substitutes to enhance wound healing. Expert Opin Investig Drugs. 1998;7:803–9.PubMedCrossRef
70.
Caravaggi C, De Giglio R, Pritelli C, et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care. 2003;26:2853–9.PubMedCrossRef
71.
Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137:822–7.PubMedCrossRef
72.
Karim RB, Brito BL, Dutrieux RP, Lassance FP, Hage JJ. MMP-2 assessment as an indicator of wound healing: a feasibility study. Adv Skin Wound Care. 2006;19:324–7.PubMedCrossRef
73.
Pirayesh A, Dessy LA, Rogge FJ, et al. The efficacy of a polyhydrated ionogen impregnated dressing in the treatment of recalcitrant diabetic foot ulcers: a multi-centre pilot study. Acta Chir Belg. 2007;107:675–81.PubMed
74.
Xie X, McGregor M, Dendukuri N. The clinical effectiveness of negative pressure wound therapy: a systematic review. J Wound Care. 2010;19:490–5.PubMed
75.
McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage. 2000;46(28–32):34.
76.
Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. Ann Vasc Surg. 2003;17:645–9.PubMedCrossRef
77.
Armstrong DG, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704–10.PubMedCrossRef
78.
79.
Kessler L, Bilbault P, Ortéga F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003;26:2378–82.PubMedCrossRef
80.
Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care. 1996;19:1338–43.PubMedCrossRef
81.
Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers. Angiology. 2011 (Epub ahead of print).
82.
Tan T, Shaw EJ, Siddiqui F, Kandaswamy P, Barry PW, Guideline Development Group. Inpatient management of diabetic foot problems: summary of NICE guidance. BMJ. 2011;342:d1280.PubMedCrossRef
83.
Hinchliffe RJ, Valk GD, Apelqvist J, et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2008;24(Suppl. 1):S119–44.PubMedCrossRef
84.
Larsson J, Apelqvist J, Agardh CD, Stenström A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabet Med. 1995;12:770–6.PubMedCrossRef
85.
Lavery LA, Wunderlich RP, Tredwell JL. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. Diabetes Res Clin Pract. 2005;70:31–7.PubMedCrossRef
Metadata
Title
Management of Diabetic Foot Ulcers
Authors
Kleopatra Alexiadou
John Doupis
Publication date
01-12-2012
Publisher
Springer Healthcare Communications
Published in
Diabetes Therapy / Issue 1/2012
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-012-0004-9

Other articles of this Issue 1/2012

Diabetes Therapy 1/2012 Go to the issue

Review

Pioglitazone in Clinical Practice: Where Are We Now?

Original Research

Initial Sulfonylurea Use and Subsequent Insulin Therapy in Older Subjects with Type 2 Diabetes Mellitus

Review

A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes

Case Report

Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin

Original Research

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study

Original Research

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits